CL2007002881A1 - Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo - Google Patents
Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodoInfo
- Publication number
- CL2007002881A1 CL2007002881A1 CL200702881A CL2007002881A CL2007002881A1 CL 2007002881 A1 CL2007002881 A1 CL 2007002881A1 CL 200702881 A CL200702881 A CL 200702881A CL 2007002881 A CL2007002881 A CL 2007002881A CL 2007002881 A1 CL2007002881 A1 CL 2007002881A1
- Authority
- CL
- Chile
- Prior art keywords
- tampon
- polyol
- excipient
- sugar
- approximately
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85318106P | 2006-10-20 | 2006-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007002881A1 true CL2007002881A1 (es) | 2008-05-09 |
Family
ID=39325098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200702881A CL2007002881A1 (es) | 2006-10-20 | 2007-10-05 | Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo |
Country Status (12)
Country | Link |
---|---|
US (2) | US7705132B2 (es) |
EP (1) | EP2094247B1 (es) |
JP (1) | JP5623743B2 (es) |
AR (1) | AR063149A1 (es) |
AU (1) | AU2007309616B2 (es) |
CA (1) | CA2666492C (es) |
CL (1) | CL2007002881A1 (es) |
ES (1) | ES2925992T3 (es) |
MX (1) | MX2009003982A (es) |
PE (1) | PE20080857A1 (es) |
TW (1) | TW200833357A (es) |
WO (1) | WO2008051363A2 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070190047A1 (en) * | 2005-07-29 | 2007-08-16 | Amgen, Inc. | Formulations that inhibit protein aggregation |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
NZ606283A (en) * | 2008-11-28 | 2014-08-29 | Abbvie Inc | Stable antibody compositions and methods for stabilizing same |
NZ595694A (en) * | 2009-05-04 | 2013-09-27 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
SG182304A1 (en) * | 2009-12-29 | 2012-08-30 | Hoffmann La Roche | Antibody formulation |
CN102946861B (zh) | 2010-03-01 | 2016-01-20 | 西托戴恩有限公司 | 浓缩蛋白制剂及其用途 |
DK2603232T3 (da) | 2010-08-11 | 2019-12-09 | Ironwood Pharmaceuticals Inc | Stabile formuleringer af linaclotid |
TW201213342A (en) | 2010-09-17 | 2012-04-01 | Baxter Int | Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral pH |
MX344727B (es) | 2010-11-11 | 2017-01-05 | Abbvie Biotechnology Ltd | Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. |
TW201247222A (en) * | 2011-04-21 | 2012-12-01 | Daiichi Sankyo Co Ltd | Antibody liquid formulation |
UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
KR102061355B1 (ko) | 2011-07-01 | 2019-12-31 | 바이오젠 엠에이 인코포레이티드 | 아르기닌-없는 tnfr : fc-융합 폴리펩티드 조성물 및 이용 방법 |
JP6113176B2 (ja) | 2011-10-18 | 2017-04-12 | コヒラス・バイオサイエンシズ・インコーポレイテッド | キシリトールによって安定化されたエタネルセプト製剤 |
US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
KR102196009B1 (ko) | 2011-10-25 | 2021-01-04 | 프로테나 바이오사이언시즈 리미티드 | 항체 제형 및 방법 |
EA029193B1 (ru) * | 2012-07-09 | 2018-02-28 | Кохерус Байосайенсис, Инк. | Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона |
FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
UA115789C2 (uk) * | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
RS60226B1 (sr) | 2012-09-07 | 2020-06-30 | Coherus Biosciences Inc | Stabilne vodene formulacije adalimumaba |
IN2015KN00452A (es) | 2012-09-11 | 2015-07-17 | Coherus Biosciences Inc | |
UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
WO2014100860A2 (en) * | 2012-12-28 | 2014-07-03 | Cellestis Limited | A cell mediated immune response assay |
US20140314778A1 (en) * | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
BR112017008923A2 (pt) | 2014-10-31 | 2017-12-26 | Glaxosmithkline Ip Dev Ltd | ?formulação em pó? |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
GB201703062D0 (en) * | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) * | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) * | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) * | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4475916A (en) * | 1982-03-18 | 1984-10-09 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) * | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) * | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) * | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4597966A (en) * | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
US4596556A (en) * | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) * | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) * | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US5237054A (en) * | 1987-02-20 | 1993-08-17 | Akzo Pharma | Stabilized aqueous composition containing antibodies |
US4941880A (en) * | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
ZA902519B (en) | 1989-04-04 | 1991-12-24 | Lilly Co Eli | Pharmaceutical formulations |
US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) * | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9122820D0 (en) * | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5955448A (en) | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
GB2288732B (en) * | 1994-04-13 | 1998-04-29 | Quadrant Holdings Cambridge | Pharmaceutical compositions |
US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9705810D0 (en) | 1997-03-20 | 1997-05-07 | Common Services Agency | Intravenous immune globulin |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
DE19937219A1 (de) * | 1999-08-06 | 2001-02-08 | Aventis Behring Gmbh | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie |
PT988861E (pt) | 1998-08-17 | 2004-06-30 | Pfizer Prod Inc | Formulacoes de proteina estabilizadas |
EP1173151B1 (en) | 1999-04-16 | 2003-07-09 | Novo Nordisk A/S | Dry, mouldable drug formulation |
EP1254666A4 (en) | 1999-12-28 | 2004-12-22 | Chugai Pharmaceutical Co Ltd | STABLE ANTIBODY COMPOSITIONS AND INJECTION FORMULATIONS |
JP5490972B2 (ja) * | 2000-08-04 | 2014-05-14 | 中外製薬株式会社 | タンパク質注射製剤 |
AU2002213441B2 (en) | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
AU3070702A (en) | 2000-11-07 | 2002-05-21 | Chiron Corp | Stabilized inteferon compositions |
CZ20032208A3 (cs) | 2001-02-23 | 2004-01-14 | Immunex Corporation | Zvýšený výtěžek aktivních proteinů |
EP1391209A4 (en) | 2001-05-30 | 2009-12-16 | Chugai Pharmaceutical Co Ltd | PROTEIN PREPARATION |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
CN1966525A (zh) * | 2001-06-13 | 2007-05-23 | 根马布股份公司 | 表皮生长因子受体(egfr)的人单克隆抗体 |
US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
DE10133394A1 (de) * | 2001-07-13 | 2003-01-30 | Merck Patent Gmbh | Flüssige Formulierung enthaltend Cetuximab |
DE60235013D1 (de) * | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
EP1441589B1 (en) | 2001-11-08 | 2012-05-09 | Abbott Biotherapeutics Corp. | Stable liquid pharmaceutical formulation of igg antibodies |
PT2308888T (pt) * | 2001-11-14 | 2017-05-03 | Janssen Biotech Inc | Anticorpos anti-il-6, composições, métodos e utilizações |
DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
WO2003066660A2 (en) | 2002-02-05 | 2003-08-14 | Immunolex Therapeutics Aps | A PAIR OF ANTIBODY Fv FRAGMENTS STABILIZED BY COILEDCOIL PEPTIDES |
US20040009168A1 (en) * | 2002-04-05 | 2004-01-15 | Elizabet Kaisheva | Multidose antibody formulation |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
NZ537610A (en) | 2002-07-02 | 2006-07-28 | Smithkline Beecham Corp | Stable formulations of the C242 antibody |
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
WO2004039337A2 (en) | 2002-10-31 | 2004-05-13 | Protein Design Labs, Inc. | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
US20040191243A1 (en) * | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
EP1589996A4 (en) | 2003-01-30 | 2009-01-21 | Medimmune Inc | ANTI-INTEGRIN ALPHA BETA 3 ANTIBODY FORMULATIONS AND ITS USES |
MXPA05008409A (es) | 2003-02-10 | 2005-10-05 | Elan Pharm Inc | Formulacion de inmunoglobulina y metodo para la preparacion de la misma. |
DE10355251A1 (de) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
FI117336B (fi) * | 2004-07-27 | 2006-09-15 | Kone Corp | Hissin koneistoalusta |
NZ554520A (en) * | 2004-10-22 | 2010-03-26 | Amgen Inc | Methods for refolding of recombinant antibodies |
MX2007010971A (es) | 2005-03-08 | 2007-09-19 | Pharmacia & Upjohn Co Llc | Composiciones de anticuerpo anti-citla-4. |
JP2008536493A (ja) * | 2005-04-01 | 2008-09-11 | アムジエン・インコーポレーテツド | 上皮増殖因子受容体遺伝子のコピー数 |
CN101495142A (zh) * | 2006-06-05 | 2009-07-29 | 健泰科生物技术公司 | 延长EGF或TGF-α水平升高的癌症患者的存活 |
US20100158925A1 (en) * | 2006-06-14 | 2010-06-24 | Meera Agarkhed | Lyophilized formulations of anti-egfr antibodies |
-
2007
- 2007-10-05 AU AU2007309616A patent/AU2007309616B2/en active Active
- 2007-10-05 US US11/973,051 patent/US7705132B2/en active Active
- 2007-10-05 WO PCT/US2007/021475 patent/WO2008051363A2/en active Application Filing
- 2007-10-05 ES ES07839333T patent/ES2925992T3/es active Active
- 2007-10-05 MX MX2009003982A patent/MX2009003982A/es active IP Right Grant
- 2007-10-05 CA CA2666492A patent/CA2666492C/en active Active
- 2007-10-05 PE PE2007001356A patent/PE20080857A1/es not_active Application Discontinuation
- 2007-10-05 CL CL200702881A patent/CL2007002881A1/es unknown
- 2007-10-05 JP JP2009533310A patent/JP5623743B2/ja active Active
- 2007-10-05 EP EP07839333.7A patent/EP2094247B1/en active Active
- 2007-10-05 TW TW096137621A patent/TW200833357A/zh unknown
- 2007-10-09 AR ARP070104421A patent/AR063149A1/es not_active Application Discontinuation
-
2010
- 2010-03-05 US US12/718,898 patent/US8241632B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20080124326A1 (en) | 2008-05-29 |
CA2666492A1 (en) | 2008-05-02 |
EP2094247A2 (en) | 2009-09-02 |
MX2009003982A (es) | 2009-04-27 |
AU2007309616B2 (en) | 2011-10-06 |
WO2008051363A2 (en) | 2008-05-02 |
TW200833357A (en) | 2008-08-16 |
JP2010506911A (ja) | 2010-03-04 |
AR063149A1 (es) | 2008-12-30 |
PE20080857A1 (es) | 2008-08-19 |
ES2925992T3 (es) | 2022-10-20 |
WO2008051363A3 (en) | 2008-09-12 |
CA2666492C (en) | 2012-07-17 |
JP5623743B2 (ja) | 2014-11-12 |
EP2094247B1 (en) | 2022-06-29 |
AU2007309616A1 (en) | 2008-05-02 |
US8241632B2 (en) | 2012-08-14 |
US7705132B2 (en) | 2010-04-27 |
US20100158908A1 (en) | 2010-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007002881A1 (es) | Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo | |
CL2007002880A1 (es) | Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor d | |
WO2006081276A8 (en) | 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | |
MY145117A (en) | Disposable diaper | |
BRPI0811805A2 (pt) | "artigo absorvente alongado e método para sua fabricação". | |
EG24514A (en) | Absorbent article with lotion-containing topsheet | |
PL1858462T3 (pl) | Wyrób chłonny typu majtek i sposób jego wytwarzania | |
SI2679676T1 (sl) | Metode in organizmi za rastno-vezano proizvodnjo 1,4-butandiola | |
EP1747530A4 (en) | COMPETITION SYSTEM AND METHODS BASED ON THE MOVEMENT OF FINANCIAL MARKETS | |
BRPI0818802A2 (pt) | Artigo absorvente que tem maciez otimizada. | |
EP1902694A4 (en) | DISPOSABLE THREAD AND MANUFACTURING METHOD THEREFOR | |
EP2047369A4 (en) | SIMULTANEOUS ACCESS CONTROL PESSIMISTIC AND OPTIMIZED COMBINED | |
PL2018184T3 (pl) | Przeciwciało Anty-VEGF-B do stosowania w leczeniu lub profilaktyce cukrzycy typu II lub zespołu metabolicznego | |
EP1978034A4 (en) | ANTI-PERIOSTINE ANTIBODIES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PERIOSTIN-RELATED DISEASE CONTAINING THE ANTIBODY | |
ZA200707773B (en) | An additive system for use in paper making and process of using the same | |
WO2011075665A3 (en) | Beta-cell replication promoting compounds and methods of their use | |
EP1752580A4 (en) | THIN TOILET PAPER AND METHOD FOR THE PRODUCTION THEREOF | |
WO2008076257A3 (en) | Treating cancer with anti-igflr antibody 19d12 = sch 717454 | |
EP2029783A4 (en) | BIOLOGICAL FIXTURE AND METHOD FOR ITS USE | |
SI1957973T1 (sl) | Sistem in postopek za določanje trenutka, ko koncentracija alkohola v krvi preseže mejno vrednost | |
TWI351035B (en) | Low-power dram and method for driving the same | |
HK1100044A1 (en) | Board for measuring parallelism of top and bottom surface tables, system for measuring the same and method of adjusting distance there between | |
IL184774A0 (en) | Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats 011 serotype | |
GB2430428B (en) | Device and method for the metering of solutions | |
BRPI0722057A2 (pt) | Composto, prodroga, composição farmacêutica, método para prevenir ou tratar distúrbio do sono, e, uso do composto. |